Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

Completed · Phase 4

Conditions studied: Schizophrenia

In brief

This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.

Key facts

Study ID

NCT00169065

Run by

Harvard Medical School (HMS and HSDM)

People needed

38

Starts

1998-08-01

Expected to finish

2002-06-01

Last updated by the study team

2015-04-07

Who can join

Age: 20 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 20-60 years;
• Diagnosis of treatment refractory schizophrenia or schizoaffective disorder;
• BPRS score > 21 (0-6) scale;
• Either two 6-8 week trials of typical neuroleptics given at a dosage of 600 mg/day of CPZ or its equivalent or one 6-8 week trial of an atypical antipsychotic at a reasonable dose (i.e. risperidone 4-6 mg/day);
• The patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent;
• Clinically appropriate for clozapine or olanzapine

You may not qualify if…

• Current substance abuse;
• Suicide or homicide risk;
• Pregnancy or lactation;
• History of seizures or blood dyscrasias

Where it is running

• Commonwealth Research Center — Jamaica Plain, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.